Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified.

Slides:

Advertisements

Similar presentations

Patients who had reported experiencing symptoms in the previous 7 days were asked during what times of the day the symptoms were most troublesome. a) Breathlessness,

Advertisements

Pulmonary response in sarcoidosis

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

In chronic haemorrhage a) several pigmented macrophages fill the alveoli with dense fibrosis of the interstitium; b) the haemosiderin pigment in macrophages.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

Exploratory pooled analysis (studies 004 and 006 combined) of a) categorical forced vital capacity change at week 72 and b) 6-min walk test distance decrement.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Smoking cessation rate as point prevalence quit rate from year 1 to 5 in the Lung Health Study with 5,587 chronic obstructive pulmonary disease patients.

Sensitivity analysis describing the features of the lymphatic control on pleural liquid volume. Sensitivity analysis describing the features of the lymphatic.

Schematic diagram of the potential psychophysiological mechanism of perception of breathlessness in obese adults with dyspnoea on exertion. 1: increased.

Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Nonspecific interstitial pneumonia fibrosing pattern in a case of connective tissue disease. a) The alveolar walls are thickened by interstitial fibrosis.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Prevalence of obstructive sleep apnoea (OSA) (apnoea/hypopnoea index ≥15 events·h−1) in a) males aged 50–69 years and b) females aged 50–69 years with.

Multimodal management of a central airway obstruction by a squamous cell carcinoma using laser and temporary carinal stent placement, followed by radiation.

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Profile of Pseudomonas aeruginosa resistance by country and antibiotic

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Forest plot comparison of mucolytics versus placebo for the number of exacerbations per patient per month. Forest plot comparison of mucolytics versus.

a) The Spiration (Spiration, Inc. , Redmond, WA, USA) device

Effect of omalizumab on change from baseline (B) in a) total asthma symptom score, b) total rhinitis symptom score, and c) combined asthma and rhinitis.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

A) Measurement of the right atrial a) area and b) long axis for calculation of right atrial volume. c) Measurement of the left ventricular eccentricity.

Significance of the principal genetic variants associated with familial pulmonary fibrosis by their strength and frequency. Significance of the principal.

Tobacco smoking as a second order schedule of reinforcement.

Oxygen uptake and carbon dioxide removal in the membrane lung

Duration of antibiotic therapy according to clinical pulmonary infection score in a randomised trial of an antibiotic discontinuation policy for clinically.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Management of patients with obesity hypoventilation syndrome (OHS) from diagnosis to integrated care to modify health trajectories. Management of patients.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Cumulative survival estimates for the subgroup of 127 patients with ventilator-associated pneumonia caused by nonfermentative Gram-negative bacilli according.

Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.

Typical example of posterior–anterior scans of the lungs after inhaling Technegas on day 1 (control; a) and after increasing doses of methacholine (b–d).

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Percentage of women using snus and/or cigarette smoke during pregnancy based on self-reported time for stopping from those who completed both 18-week and.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Representative pressure tracings of a) pulmonary arterial pressure and b) pulmonary arterial wedge pressure (PAWP). Representative pressure tracings of.

The “route to quit” model, which indicates the contribution of different ways of quitting to overall rates of smoking cessation. #: in most cases nicotine.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Reduction in craving expressed as area under the curve during 60 min for a) Nicorette 4 mg gum (♦), mouth spray (▴), lozenge (•) and placebo lozenge (▪);

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Distribution of diffusing capacity of the lung for carbon monoxide (DLCO) among 243 scleroderma patients who underwent right heart catheterisation (RHC)

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Common venovenous extracorporeal membrane oxygen configurations

Left upper lobe complete atelectasis 2 days after implantation of four endobronchial valves into the left upper lobe in a patient with emphysema. a) Chest.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Trends of mortality rates in the USA between 1930 and 2000 in males according to cancer site. –––––: stomach; ·······: prostate; –– –– ––: colon and rectum;

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

A) Reported tuberculosis cases in Sweden by country of birth, 1984–1996. b) Reported tuberculosis cases in Denmark by country of birth. ○: born abroad;

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Flow–volume loops of test breaths and preceding control breaths of a representative chronic obstructive pulmonary disease patient with different degrees.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified by expired carbon monoxide (except week 36 which was a telephone visit). Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified by expired carbon monoxide (except week 36 which was a telephone visit). Modified from [23]. Philip Tønnesen Eur Respir Rev 2013;22:37-43 ©2013 by European Respiratory Society